Sign In
Buy LXRX
$1.85
-0.0400 (-2.12%)
At Close: Jun 03, 2026
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study
10:41am, Monday, 04'th Jan 2021
Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
08:00am, Thursday, 31'st Dec 2020
THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-
Moving Average Crossover Alert: Lexicon Pharmaceuticals (LXRX)
06:47am, Thursday, 31'st Dec 2020
Lexicon Pharmaceuticals (LXRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Lexicon Pharma Sold LXRX Stock to Weight Watchers' Turn-Around Billionaire
09:56am, Wednesday, 30'th Dec 2020
Lexicon Pharma sold LXRX stock to Weight Watchers' turn-around billionaire. Lexicon sold 15% of LXRX stock to Ray Debbane's private equity company which turned Weight Watchers around.
Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More
07:19am, Sunday, 20'th Dec 2020
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying ca
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
04:05pm, Wednesday, 16'th Dec 2020
THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of precl
Why Lexicon Pharmaceuticals Flopped on Friday
06:04pm, Friday, 11'th Dec 2020
More clarification seems warranted for the company's shareholder-diluting move.
Lexicon Announces Offering of Common Stock
08:02am, Friday, 11'th Dec 2020
THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional
Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
07:38am, Friday, 11'th Dec 2020
THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administra
Why Lexicon Pharmaceuticals's Stock is Up During Today's Session
01:35pm, Tuesday, 08'th Dec 2020
Lexicon Pharmaceuticals (NASDAQ: LXRX) is currently up 93.64% to a price of $3.3. Tuesday the stock has been traded at a volume of 163.00 million, about 3138.31% of its recent 30-day volume average of
LXRX Stock: Why Lexicon Pharmaceuticals Is Soaring Tuesday
11:22am, Tuesday, 08'th Dec 2020
Lexicon Pharmaceuticals (LXRX) stock is soaring higher on Tuesday after getting an upgrade from Citi analyst Yigal Nochomovitz. The post LXRX Stock: Why Lexicon Pharmaceuticals Is Soaring Tuesday appe
Lexicon Pharmaceuticals News: Why LXRX Stock Is Soaring 43% Today
11:44am, Tuesday, 17'th Nov 2020
Lexicon Pharmaceuticals (LXRX) news for Tuesday includes LXRX stock soaring higher on results from a Phase 3 clinical trial. The post Lexicon Pharmaceuticals News: Why LXRX Stock Is Soaring 43% Today
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies Sotagliflozin Significantly Reduced Total C
Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q3 2020 Results - Earnings Call Transcript
11:45am, Thursday, 29'th Oct 2020
Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q3 2020 Results - Earnings Call Transcript
Lexicon Pharmaceuticals: Q3 Earnings Insights
08:02am, Thursday, 29'th Oct 2020
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) rose 5.7% in pre-market trading after the company reported Q3 results.
